167 related articles for article (PubMed ID: 30570833)
1. Risk of Hospitalized Infection and Initiation of Abatacept Versus Tumor Necrosis Factor Inhibitors Among Patients With Rheumatoid Arthritis: A Propensity Score-Matched Cohort Study.
Chen SK; Liao KP; Liu J; Kim SC
Arthritis Care Res (Hoboken); 2020 Jan; 72(1):9-17. PubMed ID: 30570833
[TBL] [Abstract][Full Text] [Related]
2. Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.
Xie F; Yun H; Bernatsky S; Curtis JR
Arthritis Rheumatol; 2016 Nov; 68(11):2612-2617. PubMed ID: 27213279
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of abatacept versus TNF inhibitors in rheumatoid arthritis patients who are ACPA and shared epitope positive.
Harrold LR; Wittstock K; Kelly S; Han X; Zhuo J; Schrader A; Middaugh N; Moore PC; Khaychuk V
Adv Rheumatol; 2024 Jan; 64(1):10. PubMed ID: 38243281
[TBL] [Abstract][Full Text] [Related]
4. Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study.
Kang EH; Jin Y; Brill G; Lewey J; Patorno E; Desai RJ; Kim SC
J Am Heart Assoc; 2018 Jan; 7(3):. PubMed ID: 29367417
[TBL] [Abstract][Full Text] [Related]
5. Frailty and Risk of Serious Infections in Patients With Rheumatoid Arthritis Treated With Biologic or Targeted-Synthetic Disease-Modifying Antirheumatic Drugs.
Singh N; Gold LS; Lee J; Wysham KD; Andrews JS; Makris UE; England BR; George MD; Baker JF; Jarvik J; Heagerty PJ; Singh S
Arthritis Care Res (Hoboken); 2024 May; 76(5):627-635. PubMed ID: 38116680
[TBL] [Abstract][Full Text] [Related]
6. Drug-survival profiling of second-line biologic therapy in rheumatoid arthritis: Choice of another tumour necrosis factor inhibitor or a biologic of different mode of action?
Shipa MRA; Di Cicco M; Balogh E; Nitu NA; Mainuddin MD; Bhadauria N; Mukerjee D; Roussou E
Mod Rheumatol; 2023 Jul; 33(4):700-707. PubMed ID: 35920402
[TBL] [Abstract][Full Text] [Related]
7. Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis.
Grabner M; Boytsov NN; Huang Q; Zhang X; Yan T; Curtis JR
Arthritis Res Ther; 2017 May; 19(1):92. PubMed ID: 28506320
[TBL] [Abstract][Full Text] [Related]
8. Impact of TNF inhibitor therapy on joint replacement rates in rheumatoid arthritis: a matched cohort analysis of BSRBR-RA UK registry data.
Hawley S; Ali MS; Cordtz R; Dreyer L; Edwards CJ; Arden NK; Cooper C; Judge A; Hyrich K; Prieto-Alhambra D
Rheumatology (Oxford); 2019 Jul; 58(7):1168-1175. PubMed ID: 30649521
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration.
Lauper K; Iudici M; Mongin D; Bergstra SA; Choquette D; Codreanu C; Cordtz R; De Cock D; Dreyer L; Elkayam O; Hauge EM; Huschek D; Hyrich KL; Iannone F; Inanc N; Kearsley-Fleet L; Kristianslund EK; Kvien TK; Leeb BF; Lukina G; Nordström DC; Pavelka K; Pombo-Suarez M; Rotar Z; Santos MJ; Strangfeld A; Verschueren P; Courvoisier DS; Finckh A
Ann Rheum Dis; 2022 Oct; 81(10):1358-1366. PubMed ID: 35705376
[TBL] [Abstract][Full Text] [Related]
10. Compared efficacy of rituximab, abatacept, and tocilizumab in patients with rheumatoid arthritis refractory to methotrexate or TNF inhibitors agents: a systematic review and network meta-analysis.
Pugliesi A; de Oliveira AB; Oliveira AB; Xavier R; da Mota LMH; Bertolo MB; Gonzalez-Gay MA; Citera G; de Carvalho LSF
Adv Rheumatol; 2023 Jul; 63(1):30. PubMed ID: 37415193
[TBL] [Abstract][Full Text] [Related]
11. Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial.
Balanescu AR; Citera G; Pascual-Ramos V; Bhatt DL; Connell CA; Gold D; Chen AS; Sawyerr G; Shapiro AB; Pope JE; Schulze-Koops H
Ann Rheum Dis; 2022 Nov; 81(11):1491-1503. PubMed ID: 35922124
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis-the ANSWER cohort study.
Jinno S; Onishi A; Dubreuil M; Hashimoto M; Yamamoto W; Murata K; Takeuchi T; Kotani T; Maeda Y; Ebina K; Son Y; Amuro H; Hara R; Katayama M; Saegusa J
Arthritis Res Ther; 2021 Apr; 23(1):116. PubMed ID: 33858490
[TBL] [Abstract][Full Text] [Related]
13. Effects of cytotoxic T-lymphocyte-associated protein 4 compared to TNF inhibitors on lipid profile: Results from an observational multicentre rheumatoid arthritis cohort.
Atzeni F; Cacciapaglia F; Galloways J; Manfredi A; Sakellariou G; Norton S; Gremese E; Spinelli FR; Viapiana O; Piga M; Erre GL; Bartoloni Bocci E
Autoimmun Rev; 2024 Feb; 23(2):103478. PubMed ID: 37956778
[TBL] [Abstract][Full Text] [Related]
14. Cancer risk with tocilizumab/sarilumab, abatacept, and rituximab treatment in patients with rheumatoid arthritis: a Danish cohort study.
Westermann R; Cordtz RL; Duch K; Mellemkjaer L; Hetland ML; Magnussen B; Dreyer L
Rheumatology (Oxford); 2024 Mar; ():. PubMed ID: 38452297
[TBL] [Abstract][Full Text] [Related]
15. Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment.
Simon TA; Askling J; Lacaille D; Franklin J; Wolfe F; Covucci A; Suissa S; Hochberg MC;
Arthritis Res Ther; 2010; 12(2):R67. PubMed ID: 20398273
[TBL] [Abstract][Full Text] [Related]
16. Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study.
Pawar A; Desai RJ; Gautam N; Kim SC
Lancet Rheumatol; 2020 Feb; 2(2):e84-e98. PubMed ID: 38263664
[TBL] [Abstract][Full Text] [Related]
17. Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study.
Kim SY; Schneeweiss S; Liu J; Solomon DH
J Bone Miner Res; 2012 Apr; 27(4):789-96. PubMed ID: 22162140
[TBL] [Abstract][Full Text] [Related]
18. Comparative Risk of Nonvertebral Fractures Among Patients With Rheumatoid Arthritis Treated With Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs.
Pawar A; Desai RJ; He M; Bessette L; Kim SC
ACR Open Rheumatol; 2021 Aug; 3(8):531-539. PubMed ID: 34196497
[TBL] [Abstract][Full Text] [Related]
19. Infection outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: Results from a 10-year international post-marketing study.
Simon TA; Suissa S; Skovron ML; Frisell T; Askling J; Michaud K; Pedro S; Strangfeld A; Meissner Y; Boers M; Hoffman V; Dominique A; Gomez A; Hochberg MC
Semin Arthritis Rheum; 2024 Feb; 64():152313. PubMed ID: 38044241
[TBL] [Abstract][Full Text] [Related]
20. Tofacitinib and Risk of Malignancy: Results From the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA) Study.
Khosrow-Khavar F; Desai RJ; Lee H; Lee SB; Kim SC
Arthritis Rheumatol; 2022 Oct; 74(10):1648-1659. PubMed ID: 35643956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
